Aptevo Therapeutics Inc. reported a net loss of $7.5 million, or $2.23 per share, for the three months ended September 30, 2025, compared to a net loss of $5.1 million, or $357.86 per share, for the same period in 2024. Research and development expenses increased to $4.0 million from $3.1 million, primarily due to higher mipletamig and employee costs, offset by lower costs on ALG.APV-527. General and administrative expenses rose to $3.6 million from $2.1 million, mainly due to higher employee costs. A non-cash dividend of $1.5 million was recorded related to the down round feature of warrants, increasing net loss attributable to common shareholders to $9.0 million for EPS purposes. As of September 30, 2025, cash and cash equivalents totaled $21.1 million, with an additional $4.1 million raised in October, resulting in a proforma cash position of $25.2 million. The company states it has sufficient cash resources to meet projected operating requirements for at least twelve months from the date of issuance of the financial statements.